Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.60 |
| ▸ | CA1 | P00915 | 6/20 | 0.60 |
| ▸ | CA2 | P00918 | 6/20 | 0.60 |
| ▸ | CA9 | Q16790 | 6/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005270 | 0.85 | CA12 (0.65) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1004191 | 0.84 | MEN1 (0.48) | MGLLMAPTMEN1KMT2A | |
| SCHEMBL25987718 | 0.83 | CA12 (0.67) | CA12CA1CA2CA9MGLL | |
| SCHEMBL25718686 | 0.83 | CA12 (0.56) | CA12CA1CA2CA9MGLL | |
| SCHEMBL30448507 | 0.83 | CA12 (0.56) | CA12CA1CA2CA9MGLL | |
| SCHEMBL13306449 | 0.82 | CA12 (0.58) | CA12CA1CA2CA9BCHE | |
| SCHEMBL25718483 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9MAPT | |
| SCHEMBL20982626 | 0.81 | MAPT (0.48) | MAPTTDP1MEN1KMT2A | |
| SCHEMBL21460898 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9MGLL | |
| SCHEMBL21017935 | 0.81 | CA1 (0.64) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107248-A1 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107248-A1 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011005609-A2 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107248-A1 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | SLC10A2, KCNN3, KCNN2 | CA12 824/4885CA1 166/4885CA2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.